Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cetuximab.

Richard M Goldberg1

  • 1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 27599-7305, USA. richard_m_goldberg@med.unc.edu

Nature Reviews. Drug Discovery
|June 21, 2005
PubMed
Summary
This summary is machine-generated.

Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor, crucial for cancer growth. It received accelerated FDA approval in 2004 for metastatic colorectal cancer based on tumor response rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Tumor Deposits in Colorectal Cancer: Definitions for Ninth Edition of the Tumor Node Metastasis Staging System.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.

JAMA oncology·2025
Same author

An Aspirin a Day for Improved Colorectal Cancer Outcomes.

The New England journal of medicine·2025
Same author

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).

European journal of cancer (Oxford, England : 1990)·2025
Same author

Birth Cohort Effects in Appendiceal Adenocarcinoma Incidence Across the United States.

Annals of internal medicine·2025
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026
Same journal

Pulsatile FXR agonism.

Nature reviews. Drug discovery·2026
Same journal

CRISPR strategy tackles bacterial toxin.

Nature reviews. Drug discovery·2026
Same journal

Time to peak sales: how long is the climb?

Nature reviews. Drug discovery·2026
See all related articles

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Epidermal Growth Factor Receptor (EGFR) plays a key role in the proliferation and survival of various cancer cells.
  • Targeting EGFR is a significant strategy in cancer therapy.

Purpose of the Study:

  • To evaluate the efficacy of Cetuximab as a treatment for metastatic colorectal cancer.
  • To provide data supporting the accelerated approval of Cetuximab.

Main Methods:

  • Cetuximab, a monoclonal antibody, was administered to patients with metastatic colorectal cancer.
  • Tumor response rates from Phase II clinical trials were the primary basis for evaluation.

Main Results:

  • The study demonstrated significant tumor response rates in patients treated with Cetuximab.

Related Experiment Videos

  • These response rates met the criteria for accelerated approval.

    • Conclusions:

    • Cetuximab is an effective therapeutic option for metastatic colorectal cancer.
    • The drug's efficacy in tumor response supported its expedited regulatory review.